for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

67.78USD

Change

0.71(+1.06%)

Volume

6,166,971

Today's Range

66.70

 - 

67.92

52 Week Range

56.56

 - 

85.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
67.07
Open
67.00
Volume
6,166,971
3M AVG Volume
202.84
Today's High
67.92
Today's Low
66.70
52 Week High
85.97
52 Week Low
56.56
Shares Out (MIL)
1,253.53
Market Cap (MIL)
84,074.13
Forward P/E
9.87
Dividend (Yield %)
4.06

Next Event

Q4 2020 Gilead Sciences Inc Earnings Release

Latest Developments

More

Gilead And Vir Biotechnology Establish Clinical Collaboration To Explore Functional Cure For Chronic Hepatitis B Virus

Gilead Sciences Sees FY 2020 Non-GAAP Earnings Per Share $6.98 To $7.08

Gilead Sciences Says Kite's Tecartus Granted Conditional Marketing Authorization For Treatment Of Relapsed Or Refractory Mantle Cell Lymphoma In Europe

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer, Executive Vice President

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Jyoti Mehra

Executive Vice President of Human Resources

Linda Higgins

Senior Vice President - Head of External Innovation

Key Stats

2.44 mean rating - 32 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

26.1K

2018

22.1K

2019

22.4K

2020(E)

24.1K
EPS (USD)

2017

8.840

2018

6.670

2019

6.630

2020(E)

6.797
Price To Earnings (TTM)
69.69
Price To Sales (TTM)
3.63
Price To Book (MRQ)
4.82
Price To Cash Flow (TTM)
31.87
Total Debt To Equity (MRQ)
167.90
LT Debt To Equity (MRQ)
159.31
Return on Investment (TTM)
2.45
Return on Equity (TTM)
2.06

Latest News

Latest News

U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent fight with Gilead

The U.S. Supreme Court on Tuesday rejected Merck & Co Inc's bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent fight with Gilead

The U.S. Supreme Court on Tuesday rejected Merck & Co Inc's bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

Gilead raises 2020 profit forecast on remdesivir strength

Gilead Sciences Inc raised its full-year profit forecast on Monday, as a recent resurgence in COVID-19 cases boosted demand for its COVID-19 treatment, remdesivir.

Gilead raises 2020 profit forecast

Gilead Sciences Inc raised its full-year profit forecast on Monday, boosted by increased sales of COVID-19 treatment remdesivir, as hospitalization and treatment rates were higher than expected given the most recent surge in cases.

U.S. must face Gilead breach of contract claims in patent dispute

The U.S. government must face claims by Gilead Sciences Inc that it breached contracts with the drugmaker by obtaining and asserting patents related to the company's HIV preventive drug Truvada, a federal judge has ruled.

Gilead says not to pursue U.S. approval for rheumatoid arthritis drug

Gilead Sciences Inc said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration's approval for its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

Gilead abandons filgotinib for rheumatoid arthritis in U.S.

Gilead Sciences Inc said on Tuesday it had decided not to pursue the U.S. Food and Drug Administration's approval of its experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

EU drugs regulator endorses changes to remdesivir marketing for COVID-19 use

Europe's drugs regulator on Friday recommended changing some terms of the conditional approval given to antiviral drug remdesivir as a COVID-19 treatment, to make clear the conditions under which it can be used.

Gilead to acquire German biotech firm MYR for about 1.15 billion euros

Gilead Sciences Inc said on Thursday it will acquire MYR GmbH for about 1.15 billion euros ($1.39 billion) in cash, giving it access to the German biotech company's treatment for a severe form of viral hepatitis.

UPDATE 1-Gilead to acquire German biotech firm MYR for about 1.15 bln euros

Gilead Sciences Inc said on Thursday it will acquire MYR GmbH for about 1.15 billion euros ($1.39 billion) in cash, giving it access to the German biotech company's treatment for a severe form of viral hepatitis.

Don't use Gilead's remdesivir in hospitalised COVID-19 patients, WHO says

Gilead's remdesivir should not be used for patients hospitalised with COVID-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said on Friday.

EU says no change to uses of Gilead's remdesivir after WHO guidance

The European Commission on Friday said there had been no change in the authorised uses of Gilead's remdesivir after the World Health Organization advised against using the antiviral for treating hospitalised COVID-19 patients.

Eli Lilly arthritis drug gets FDA nod for emergency use with remdesivir to treat COVID-19

The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat COVID-19 patients.

Indian demand for COVID-19 drug remdesivir rising sharply - Cipla

Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness.

Germany says remdesivir useful for some COVID-19 patients

Germany's health minister defended on Tuesday his decision to purchase additional supplies of remdesivir for treating COVID-19, saying Gilead's antiviral drug was useful especially early in the course of the disease.

Germany requests 5% of EU supply of remdesivir

Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the antiviral drug's effectiveness in treating COVID-19.

Russian firm seeks to produce COVID-19 drug remdesivir without patent

Russian drugmaker Pharmasyntez has asked the Kremlin to allow it to produce a generic version of U.S. COVID-19 drug remdesivir, used to treat U.S. President Donald Trump, despite lacking a patent to do so, the firm's director said on Monday.

Russian firm seeks to produce COVID-19 drug without patent, Vedomosti reports

Russian drugmaker Pharmasyntez has asked the Kremlin for permission to produce a generic version of U.S. firm Gilead Sciences's COVID-19 treatment remdesivir without а patent, the Vedomosti newspaper reported on Monday.

Gilead cuts 2020 sales outlook as COVID-19 drug remdesivir falls short

Gilead Sciences Inc <GILD.O> on Wednesday cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with COVID-19.

Gilead quarterly revenue rises 17% on remdesivir sales

Gilead Sciences Inc reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up